Patients will be randomised
in a competitive recruitment process from
participating centres over 5 years. Randomisation will be
done via direct web randomisation, and patients will be
stratified by study centre, tumour type (Dukes C colon,
high risk Dukes B colon cancer & rectal cancer subgroups)
and type of adjuvant chemotherapy received
(exposed/not exposed to oxaliplatin).